Cited by 55Protein Degradation and InhibitorsCell Image Analysis TechniquesComputational Drug Discovery Methods

Cell Morphological Profiling Enables High-Throughput Screening for PROteolysis TArgeting Chimera (PROTAC) Phenotypic Signature

Open access
Trapotsi, Maria-Anna, Mouchet, Elizabeth, Williams, Guy, Monteverde, Tiziana, Juhani, Karolina, Turkki, Riku, Miljković, Filip, Martinsson, Anton +7 more·2022·ACS Chemical Biology

Published version of a preprint

Abstract

PROteolysis TArgeting Chimeras (PROTACs) use the ubiquitin-proteasome system to degrade a protein of interest for therapeutic benefit. Advances made in targeted protein degradation technology have been remarkable, with several molecules having moved into clinical studies. However, robust routes to assess and better understand the safety risks of PROTACs need to be identified, which is an essential step toward delivering efficacious and safe compounds to patients. In this work, we used Cell Painting, an unbiased high-content imaging method, to identify phenotypic signatures of PROTACs. Chemical clustering and model prediction allowed the identification of a mitotoxicity signature that could not be expected by screening the individual PROTAC components. The data highlighted the benefit of unbiased phenotypic methods for identifying toxic signatures and the potential to impact drug design.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acschembio.2c00076

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Pedregosa F.; Varoquaux G.; Gramfort A.; Michel V.; Thirion B.; Blondel M. G. O.; Prettenhofer P.; Weiss R.; D V. Scikit-Learn: Machine Learning in Python. J. Mach. Learn. Res. 2011, 12, 2825– 2830.

Cited by

Sorted by citations

Authors
Trapotsi, M.-A., Mouchet, E., Williams, G., Monteverde, T., Juhani, K., Turkki, R., Miljković, F., Martinsson, A., Mervin, L., Pryde, K. R., Müllers, E., Barrett, I., Engkvist, O., Bender, A., & Moreau, K.
Affiliations
  • AstraZeneca (United Kingdom) (GB)
  • AstraZeneca (Sweden) (SE)
  • University of Cambridge (GB)
  • Safety Innovation, Clinical Pharmacology and Safety Sciences R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
Venue
ACS Chemical Biology
Published
2022-07-06
Volume
17
Issue
7
Pages
1733-1744
ISSN
  • 1554-8929 (ISSN-L)
  • 1554-8937
OpenAlex
W4284671611
Cited by
51
References
40
Citations by year
2026: 8 · 2025: 8 · 2024: 16 · 2023: 16 · 2022: 3
FWCI
3.83
Type
journal article
Language
en
Open access
Locations
  • ACS Chemical Biology (publishedVersion, cc-by-nc-nd)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by-nc-nd)
  • Apollo
Funders
  • AstraZeneca
  • Biotechnology and Biological Sciences Research Council (BB/M011194/1)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biophysics › Cell Image Analysis Techniques
  • Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
Keywords
PROTACs, targeted protein degradation, Cell Painting, phenotypic profiling, mitochondrial toxicity, drug safety, chemical clustering, model prediction, high-content imaging, ubiquitin-proteasome system
MeSH terms
Humans, Ubiquitin-Protein Ligases, Proteasome Endopeptidase Complex, High-Throughput Screening Assays, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review